论文部分内容阅读
目的 :探讨经肝癌瘤苗激活的 TIL 治疗原发性肝癌的作用。方法 :使用冷冻方法制成肝癌瘤苗 ,用于激活 TIL。对 2 6例原发性肝癌患者使用经肝癌瘤苗激活的 TIL 治疗 ,并检测治疗前后其 CD3、CD4、CD8、CD4/CD8比值和 NK活性的变化 ,计算其 1a、2 a、3a生存率 ,并与对照组相比较。结果 :应用经肝癌瘤苗激活的 TIL 患者 ,其 CD3、CD4、CD4/ CD8比值和 NK活性明显升高 ,CD8则明显下降 ,其 3 a生存率明显升高。结论 :应用经肝癌瘤苗激活的 TIL治疗 ,能明显地提高原发性肝癌患者的免疫功能和远期疗效
Objective: To investigate the role of TIL activated by liver cancer vaccine in the treatment of primary liver cancer. Methods: A hepatoma vaccine was made by freezing to activate TIL. Twenty-six patients with primary hepatocellular carcinoma (HCC) were treated with TIL-activated TIL and the changes of CD3, CD4, CD8, CD4 / CD8 ratio and NK activity before and after treatment were measured. The survival rates of 1a, 2 a, , And compared with the control group. Results: The T lymphocytes activated by HCC vaccine showed significantly higher CD3, CD4, CD4 / CD8 ratio and NK activity, while CD8 decreased significantly. The 3-year survival rate was significantly higher. Conclusion: The application of TIL-activated hepatoma vaccine can significantly improve the immune function and long-term efficacy of patients with primary liver cancer